{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:14:03Z","timestamp":1765808043521,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.81672606"],"award-info":[{"award-number":["No.81672606"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020MH077"],"award-info":[{"award-number":["ZR2020MH077"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Jingjian Pathology Development Foundation","award":["JJlS2021-004"],"award-info":[{"award-number":["JJlS2021-004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Our purpose is to evaluate the correlation of TILs with clinicopathological characteristics and disease free survival (DFS) in DCIS and DCIS-Mi breast cancer (BC) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed the data of 360 DCIS\u00a0patients and 125 DCIS-Mi patients treated by a single institution from 2016 to 2019. TILs are regarded as continuous variables and are divided into low (\u2264\u20095%), medium (5\u201340%) and high (\u2265\u200940%) for statistical analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In DCIS and DCIS-Mi patients, larger tumor size, higher nuclear grade, hormone receptor (HR) negativity and human epidermal growth factor receptor 2(HER2) overexpression are all related to high TILs (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). In addition, compared with DCIS, DCIS-Mi patients were significantly associated with high TILs (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Based on the different results of the subtypes, we further studied the correlation between TILs and DFS in 279 cases of HER2+ patients (204 of DCIS; 75 of DCIS-Mi). In HER2+ group, DCIS-Mi was significantly associated with HR negativity (<jats:italic>P<\/jats:italic>\u2009=\u20090.015) and high TILs (<jats:italic>P<\/jats:italic>\u2009=\u20090.002) compared with DCIS patients. In the survival analysis, we found that TILs had no effect on the DFS of DCIS (<jats:italic>P<\/jats:italic>\u2009=\u20090.938), DCIS-Mi (<jats:italic>P<\/jats:italic>\u2009=\u20090.807), and HER2+ (<jats:italic>P<\/jats:italic>\u2009=\u20090.379) BC patients. In the univariate and multivariate cox regression analysis, the correlation between TILs and the prognosis of DFS has not been confirmed in the three BC groups (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>TILs have played an non-negligible role in the progress of DCIS to DCIS-Mi, especially in HER2+ BC. The predictive and prognostic value of TILs still needs further research to confirm.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-022-06553-z","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T17:03:01Z","timestamp":1646758981000},"page":"111-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast"],"prefix":"10.1007","volume":"193","author":[{"given":"Huiqing","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoxu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianning","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2093-4463","authenticated-orcid":false,"given":"Chengqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"issue":"12","key":"6553_CR1","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1016\/j.humpath.2013.07.010","volume":"44","author":"L Shatat","year":"2013","unstructured":"Shatat L, Gloyeske N, Madan R, O\u2019Neil M, Tawfik O, Fan F (2013) Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics. Hum Pathol 44(12):2684\u20132689","journal-title":"Hum Pathol"},{"issue":"1","key":"6553_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-019-05272-2","volume":"177","author":"XY Chen","year":"2019","unstructured":"Chen XY, Yeong J, Thike AA, Bay BH, Tan PH (2019) Prognostic role of immune infiltrates in breast ductal carcinoma in situ. Breast Cancer Res Treat 177(1):17\u201327","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"6553_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00428-020-02959-6","volume":"478","author":"XY Chen","year":"2021","unstructured":"Chen XY, Thike AA, Koh VCY, Nasir NDM, Bay BH, Tan PH (2021) Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence. Virchows Arch 478(4):679\u2013686","journal-title":"Virchows Arch"},{"issue":"11","key":"6553_CR4","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/biomedicines9111687","volume":"9","author":"B Henriques","year":"2021","unstructured":"Henriques B, Mendes F, Martins D (2021) Immunotherapy in breast cancer: when, how, and what challenges? Biomedicines 9(11):1687","journal-title":"Biomedicines"},{"issue":"2","key":"6553_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/annonc\/mdw623","volume":"28","author":"G Pruneri","year":"2017","unstructured":"Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A et al (2017) The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol 28(2):321\u2013328","journal-title":"Ann Oncol"},{"issue":"1","key":"6553_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE et al (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19(1):40\u201350","journal-title":"Lancet Oncol"},{"key":"6553_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/1471-2407-13-258","volume":"13","author":"H Yuan","year":"2013","unstructured":"Yuan H, Hsiao YH, Zhang Y, Wang J, Yin C, Shen R et al (2013) Destructive impact of T-lymphocytes, NK and Mast cells on basal cell layers: implications for tumor invasion. BMC Cancer 13:258","journal-title":"BMC Cancer"},{"issue":"7","key":"6553_CR8","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","volume":"25","author":"AE Giuliano","year":"2018","unstructured":"Giuliano AE, Edge SB, Hortobagyi GN (2018) Eighth edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol 25(7):1783\u20131785","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"6553_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/his.14091","volume":"77","author":"PH Tan","year":"2020","unstructured":"Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S et al (2020) The 2019 World Health Organization classification of tumours of the breast. Histopathology 77(2):181\u2013185","journal-title":"Histopathology"},{"issue":"5","key":"6553_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 1: Assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol 24(5):235\u2013251","journal-title":"Adv Anat Pathol"},{"issue":"2","key":"6553_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259\u2013271","journal-title":"Ann Oncol"},{"issue":"1","key":"6553_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10549-014-3151-z","volume":"148","author":"Y Liu","year":"2014","unstructured":"Liu Y, Colditz GA, Gehlert S, Goodman M (2014) Racial disparities in risk of second breast tumors after ductal carcinoma in situ. Breast Cancer Res Treat 148(1):163\u2013173","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"6553_CR13","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1002\/cncr.32200","volume":"125","author":"Y Liu","year":"2019","unstructured":"Liu Y, West R, Weber JD, Colditz GA (2019) Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ. Cancer 125(18):3225\u20133233","journal-title":"Cancer"},{"issue":"2","key":"6553_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41379-019-0331-8","volume":"33","author":"MC Agahozo","year":"2020","unstructured":"Agahozo MC, van Bockstal MR, Groenendijk FH, van den Bosch TPP, Westenend PJ, van Deurzen CHM (2020) Ductal carcinoma in situ of the breast: immune cell composition according to subtype. Mod Pathol 33(2):196\u2013205","journal-title":"Mod Pathol"},{"issue":"1","key":"6553_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12885-018-4013-6","volume":"18","author":"M Beguinot","year":"2018","unstructured":"Beguinot M, Dauplat MM, Kwiatkowski F, Lebouedec G, Tixier L, Pomel C et al (2018) Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. BMC Cancer 18(1):129","journal-title":"BMC Cancer"},{"issue":"8","key":"6553_CR16","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41379-018-0040-8","volume":"31","author":"MS Toss","year":"2018","unstructured":"Toss MS, Miligy I, Al-Kawaz A, Alsleem M, Khout H, Rida PC et al (2018) Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Mod Pathol 31(8):1226\u20131236","journal-title":"Mod Pathol"},{"issue":"1","key":"6553_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/ajcp\/aqw097","volume":"146","author":"A Kim","year":"2016","unstructured":"Kim A, Heo SH, Kim YA, Gong G, Jin Lee H (2016) An Examination of the local cellular immune response to examples of both ductal carcinoma in situ (DCIS) of the breast and DCIS with microinvasion, with emphasis on tertiary lymphoid structures and tumor infiltrating lymphoctytes. Am J Clin Pathol 146(1):137\u2013144","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"6553_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s10549-017-4572-2","volume":"167","author":"V Sopik","year":"2018","unstructured":"Sopik V, Sun P, Narod SA (2018) Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. Breast Cancer Res Treat 167(3):787\u2013795","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"6553_CR19","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1245\/s10434-019-07556-9","volume":"26","author":"CD Champion","year":"2019","unstructured":"Champion CD, Ren Y, Thomas SM, Fayanju OM, Rosenberger LH, Greenup RA et al (2019) DCIS with microinvasion: is it in situ or invasive disease? Ann Surg Oncol 26(10):3124\u20133132","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"6553_CR20","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/bjs.10889","volume":"105","author":"J de Boniface","year":"2018","unstructured":"de Boniface J, Frisell J, Bergkvist L, Andersson Y (2018) Breast-conserving surgery followed by whole-breast irradiation offers survival benefits over mastectomy without irradiation. Br J Surg 105(12):1607\u20131614","journal-title":"Br J Surg"},{"issue":"1","key":"6553_CR21","doi-asserted-by":"publisher","first-page":"1875637","DOI":"10.1080\/2162402X.2021.1875637","volume":"10","author":"FF Xu","year":"2021","unstructured":"Xu FF, Zheng SF, Xu C, Cai G, Wang SB, Qi WX et al (2021) Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ. Oncoimmunology 10(1):1875637","journal-title":"Oncoimmunology"},{"issue":"6","key":"6553_CR22","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/his.14055","volume":"76","author":"AA Thike","year":"2020","unstructured":"Thike AA, Chen X, Koh VCY, Binte Md Nasir ND, Yeong JPS, Bay BH et al (2020) Higher densities of tumour-infiltrating lymphocytes and CD4(+) T cells predict recurrence and progression of ductal carcinoma in situ of the breast. Histopathology 76(6):852\u2013864","journal-title":"Histopathology"},{"issue":"2","key":"6553_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10549-019-05389-4","volume":"178","author":"X Wang","year":"2019","unstructured":"Wang X, Kong X, Fang Y, Wang J (2019) Letter regarding Sopik V et al. entitled \u201cImpact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ.\u201d Breast Cancer Res Treat 178(2):481\u2013482","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"6553_CR24","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/annonc\/mdu235","volume":"25","author":"C Denkert","year":"2014","unstructured":"Denkert C (2014) The immunogenicity of breast cancer\u2013molecular subtypes matter. Ann Oncol 25(8):1453\u20131455","journal-title":"Ann Oncol"},{"issue":"1","key":"6553_CR25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12885-018-4441-3","volume":"18","author":"JP Bates","year":"2018","unstructured":"Bates JP, Derakhshandeh R, Jones L, Webb TJ (2018) Mechanisms of immune evasion in breast cancer. BMC Cancer 18(1):556","journal-title":"BMC Cancer"},{"issue":"1","key":"6553_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13058-020-01267-w","volume":"22","author":"M Kim","year":"2020","unstructured":"Kim M, Chung YR, Kim HJ, Woo JW, Ahn S, Park SY (2020) Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res 22(1):32","journal-title":"Breast Cancer Res"},{"issue":"3","key":"6553_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/modpathol.2015.158","volume":"29","author":"E Thompson","year":"2016","unstructured":"Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN et al (2016) The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol 29(3):249\u2013258","journal-title":"Mod Pathol"},{"issue":"10","key":"6553_CR28","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/s41416-020-0797-7","volume":"122","author":"MS Toss","year":"2020","unstructured":"Toss MS, Abidi A, Lesche D, Joseph C, Mahale S, Saunders H et al (2020) The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. Br J Cancer 122(10):1496\u20131506","journal-title":"Br J Cancer"},{"issue":"3","key":"6553_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","volume":"24","author":"LA Emens","year":"2018","unstructured":"Emens LA (2018) Breast cancer immunotherapy: facts and hopes. Clin Cancer Res 24(3):511\u2013520","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6553_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-016-4036-0","volume":"161","author":"MJ Campbell","year":"2017","unstructured":"Campbell MJ, Baehner F, O\u2019Meara T, Ojukwu E, Han B, Mukhtar R et al (2017) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat 161(1):17\u201328","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"6553_CR31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/path.5406","volume":"250","author":"PI Gonzalez-Ericsson","year":"2020","unstructured":"Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM et al (2020) The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol 250(5):667\u2013684","journal-title":"J Pathol"},{"key":"6553_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fimmu.2020.00176","volume":"11","author":"Z Wang","year":"2020","unstructured":"Wang Z, Cao YJ (2020) Adoptive cell therapy targeting neoantigens: a frontier for cancer research. Front Immunol 11:176","journal-title":"Front Immunol"},{"key":"6553_CR33","doi-asserted-by":"publisher","first-page":"690499","DOI":"10.3389\/fimmu.2021.690499","volume":"12","author":"A Kumar","year":"2021","unstructured":"Kumar A, Watkins R, Vilgelm AE (2021) Cell therapy with TILs: training and taming T cells to fight cancer. Front Immunol 12:690499","journal-title":"Front Immunol"},{"issue":"4","key":"6553_CR34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1158\/2326-6066.CIR-19-0786","volume":"8","author":"CR Gil Del Alcazar","year":"2020","unstructured":"Gil Del Alcazar CR, Aleckovic M, Polyak K (2020) Immune escape during breast tumor progression. Cancer Immunol Res 8(4):422\u2013427","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"6553_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-021-06287-4","volume":"189","author":"P Savas","year":"2021","unstructured":"Savas P, Salgado R, Loi S (2021) Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. Breast Cancer Res Treat 189(3):599\u2013606","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06553-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T03:34:46Z","timestamp":1649475286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06553-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["6553"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06553-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2022,3,8]]},"assertion":[{"value":"25 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}